SCHEMBL5714809

SCHEMBL5714809

Cc1ccc(CCc2ccc(OC(=O)N3CCN(c4ccc(Cl)cn4)CC3)cc2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 3/20 0.47
AOC3 Q16853 3/20 0.47
ME2 P23368 4/20 0.46
ME1 P48163 4/20 0.46
ME3 Q16798 4/20 0.46
TRPA1 O75762 1/20 0.43
TACR3 P29371 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
DRD4 P21917 1/20 0.40
DRD5 P21918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715223 0.94 AOC3 (0.52) PANK3AOC3ME2ME1ME3
SCHEMBL5714779 0.91 PANK3 (0.50) PANK3ME2ME1ME3TRPA1
SCHEMBL5715218 0.89 DRD2 (0.49) PANK3AOC3ME2ME1ME3
SCHEMBL5714320 0.88 AOC3 (0.47) PANK3AOC3ME2ME1ME3
SCHEMBL5714583 0.88 AOC3 (0.47) PANK3AOC3ME2ME1ME3
SCHEMBL5715391 0.87 PANK3 (0.46) PANK3AOC3ME2ME1ME3
SCHEMBL5715372 0.86 SMN1; SMN2 (0.60) PANK3AOC3HRH3HPGDSMN1; SMN2
SCHEMBL5715476 0.86 KDM4E (0.54) AOC3HPGDSMN1; SMN2
SCHEMBL5715861 0.85 PANK3 (0.46) PANK3AOC3ME2ME1ME3
SCHEMBL5714218 0.85 PANK3 (0.53) PANK3AOC3ME2ME1ME3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC PANK3 1247/4885AOC3 2256/4885ME2 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.